Aflac account plan
Employee benefits insurance policies
At a glance
Aflac sells supplemental health and life insurance in Japan and the U.S., with FY2025 total revenues of $17.2 billion and 12,716 full-time employees.
Aflac Incorporated, based in Columbus, Georgia, sells supplemental health and life insurance that pays cash benefits when a policyholder gets sick or hurt, covering costs not reimbursed by primary coverage. It operates in Japan, where it is the largest insurer by cancer and medical policies in force, and in all 50 U.S. states, selling through agents, brokers, banks and alliance partners. FY2025 total revenues fell 9.3% to $17.2 billion on investment losses, net earnings were $3.6 billion and adjusted earnings $4.0 billion ($7.49 per diluted share). It had 12,716 full-time employees at end-2025. Daniel P. Amos is Chairman and CEO.
Business units
Aflac Japan
53% of FY2025 total adjusted revenues ($9,357 million)Cancer, medical and nursing care insurance plus protection and savings life products such as Tsumitasu, sold through about 6,300 agencies, alliances with Dai-ichi Life, Japan Post Group and Daido Life, and 358 banks. It holds about 22 million policies, about 14 million of them cancer policies. 2025 sales rose 16.0% in yen to ¥74.4 billion on the Miraito cancer product; pretax adjusted earnings were $3,440 million. Shinsuke Morimoto becomes President from January 1.
Aflac U.S.
about 39% of FY2025 total adjusted revenues ($6,903 million)Individual and group accident, disability, cancer and critical illness, hospital indemnity, network dental and vision and life insurance, sold by career agents to small businesses and brokers to larger employers. Net earned premiums rose 2.9% to $5,999 million in 2025, and Q3 2026 pretax adjusted earnings rose 31.5% to $493 million. Fred Simard becomes President from January 1.
Corporate and other
about 7% of FY2025 total adjusted revenues ($1,277 million)The parent company, asset managers, Aflac Global Ventures and Aflac Re Bermuda, which reinsures cancer policies issued by Aflac Japan; pretax adjusted earnings were $101 million in 2025.
Strategic priorities
- Japan sales growth
- Promote Miraito, Tsumitasu and the Anshin Palette medical product; Amos expects 2026 Japan sales to exceed 2025, with nine-month sales up 3.0%.
- U.S. growth platforms
- Grow group life, absence and disability, consumer markets and dental and vision, which grew 15% in Q3 2026 with dental and vision up 67%.
- Capital efficiency through reinsurance
- Internal reinsurance target raised to up to 30% of FSA reserves; about 500 billion yen of cancer reserves ceded to Aflac Re Bermuda, releasing about $1 billion of capital over time.
- Investment repositioning
- $7 billion repositioned through switch trades in 2026, mostly JGBs, to capture higher yields.
- Capital return
- $2.8 billion of buybacks in nine months of 2026 and 44 consecutive years of dividend increases.
Latest results
In Q3 2026 total revenues fell to $3.3 billion from $4.7 billion because of $1.1 billion of net investment losses, largely from repositioning the portfolio, and net earnings fell to $303 million ($.61 per diluted share). Adjusted earnings were $1.2 billion, or $2.43 per diluted share, against $2.49. Aflac Japan pretax adjusted earnings fell 15.2% in yen and sales fell 4.0% to ¥18.8 billion against the Miraito launch baseline, while Aflac U.S. pretax adjusted earnings rose 31.5%. Aflac now expects 2026 benefit ratios slightly below 60%-63% in Japan and below 48%-52% in the U.S.
Investments and deals
- Aflac Re cancer reinsurance
- A new internal cancer reinsurance transaction with Aflac Re in Q3 2026, after one established in Q4 2024, plus an external reinsurance transaction in Q1 2026.
- Portfolio switch trades
- $4.8 billion repositioned by Q2 2026, expected to add over $50 million of run-rate net investment income, rising to $7 billion by Q3.
- Share repurchases
- $3.5 billion of buybacks in 2025 and $2.8 billion in the first nine months of 2026.
- Product launches
- Miraito cancer insurance (March 2025), Tsumitasu savings life (June 2024) and Anshin Palette medical insurance (December 2025).
Challenges and risks
- Cyber incidents
- The June 2025 U.S. incident involved personal information of approximately 22.65 million individuals, and a June 25, 2026 Aflac Japan incident paused direct mail and outbound calls.
- Shrinking Japan premiums
- Japan net earned premiums fell 2.0% in yen in Q3 2026 from reinsurance and paid-up policies; annualized premiums in force fell 2.2% to ¥1.16 trillion.
- Yen and Japan concentration
- Concentration in Japan and in JGBs, yen/dollar exposure and interest rates are key risks; the yen was 6.8% weaker in Q3 2026.
- Group disability claims
- Higher incurred group disability claims lifted the U.S. benefit ratio to 49.5% in Q2 2026.
- Competition in U.S. supplemental lines
- Major medical carriers are entering supplemental lines, bundling and discounting.
What leadership says
“reduce risk, improve balance sheet efficiency, and ultimately generate a higher ROE”
“the more we do, the harder it is to find additional opportunities”
“long-term and deliberate succession planning”
Where a supplier can help
- Cybersecurity and data protection
- Tied to the cyber incidents challenge: two breaches in the U.S. and Japan raise the need for security, monitoring and incident response.
- Benefits distribution technology
- Tied to the U.S. growth platforms priority: group, dental and vision and consumer-markets growth relies on broker platforms, enrollment and digital lead generation.
- Claims management for disability
- Tied to the group disability claims challenge: claims analytics and absence management tools.
- Japan marketing operations
- Tied to the Japan sales growth priority: direct mail, outbound and agency channels that were paused after the Japan cyber incident.
- Investment and reinsurance analytics
- Tied to the capital efficiency and investment repositioning priorities: ALM, reinsurance and portfolio tools.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Aflac?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Aflac Incorporated Form 10-K for fiscal year 2025
- Aflac Incorporated (Columbus, Georgia; incorporated 1973) sells supplemental health and life insurance in Japan and the U.S. through two reporting segments, Aflac Japan and Aflac U.S., plus Corporate and other (incl. the Bermuda reinsurer Aflac Re); 12,716 full-time employees at end-2025.
- FY2025: total revenues down 9.3% to $17.2 billion (net investment losses of $572 million vs gains of $1.3 billion in 2024); net earnings $3.6 billion ($6.82 per diluted share) vs $5.4 billion ($9.63); adjusted earnings $4.0 billion, or $7.49 per diluted share vs $7.21.
- Aflac Japan is the principal earnings contributor: 53% of total adjusted revenues and 76% of total assets; pretax adjusted earnings $3,440 million; the largest insurer in Japan by cancer and medical policies in force, with about 22 million policies and about 14 million cancer policies.
- Aflac Japan new annualized premium sales rose 16.0% in yen to ¥74.4 billion, driven by the Miraito cancer product (launched March 2025) and Tsumitasu; a new medical product, Anshin Palette, launched December 2025.
- Aflac U.S.: net earned premiums $5,999 million (+2.9%), pretax adjusted earnings $1,421 million, new annualized premium sales $1,589 million (+3.0%) driven by group products; growth lines are group life, disability, network dental and vision and direct-to-consumer.
- Capital return: $3.5 billion of share repurchases in 2025; dividends of $2.32 per share (+16.0%); a 5.2% quarterly dividend increase from Q1 2026. ESR target 170%-230% for Aflac Japan, combined RBC target 350%-450% for Aflac U.S. (estimated at 570% at year-end).
- 2026 outlook: Aflac Japan benefit ratio 60%-63% and expense ratio 20%-23%; Aflac U.S. benefit ratio 48%-52% and expense ratio 36%-39%.
- Key risks: concentration in Japan and in JGBs, yen/dollar exposure, interest rates, credit; the June 2025 U.S. cyber incident involved personal information of approximately 22.65 million individuals, not judged reasonably likely to be material.
- Aflac Incorporated Form 10-Q for the quarter ended September 30, 2026
- Q3 2026: total revenues $3.3 billion vs $4.7 billion, because of $1.1 billion of net investment losses largely from a strategic repositioning of the investment portfolio; net earnings $303 million ($.61 per diluted share) vs $1.6 billion ($3.08).
- Adjusted earnings $1.2 billion, or $2.43 per diluted share, vs $2.49; nine-month adjusted EPS flat at $5.92. The yen averaged 158.49, 6.8% weaker, costing $.03 of adjusted EPS in the quarter.
- Aflac Japan: pretax adjusted earnings ¥152 billion (-15.2%) as assumption-update remeasurement gains were smaller than in Q3 2025; Q3 sales ¥18.8 billion (-4.0%) against the Miraito launch baseline, but nine-month sales +3.0% on Tsumitasu and Anshin Palette.
- An unauthorized third party accessed Aflac Japan systems on June 25, 2026; marketing such as direct mail and outbound calls was paused in Q3 and had resumed by quarter end; costs raised Japan expenses.
- New internal cancer reinsurance with Aflac Re in Q3 2026 and an external reinsurance transaction in Q1 2026 reduced Japan earned premiums.
- Aflac U.S.: net earned premiums $1,544 million (+3.3%), pretax adjusted earnings $493 million (+31.5%), margin 27.7%; sales $403 million (+3.5%) driven by group products; persistency 79.7%.
- 2026 benefit ratios now expected slightly below 60%-63% in Japan and below 48%-52% in the U.S.
- $2.8 billion of buybacks in nine months; $3.7 billion returned to shareholders; Q4 dividend $.61 per share (+5.2%); Aflac Japan made its first ESR disclosure (as of March 31, 2026) in July 2026.
- Aflac Incorporated Q3 2026 earnings call transcript
- Dan Amos opened with leadership succession effective January 1: Shinsuke Morimoto to become President of Aflac Japan, Fred Simard President of Aflac U.S.; Masatoshi Koide to become Chairman of Aflac Japan and Charles Lake Chairman of Aflac International.
- Q3 2026 net earnings of 61 cents and adjusted earnings of $2.43 per diluted share; Aflac Japan sales fell 4% to 18.8 billion yen against the Miraito launch comparison but were up 3% over nine months; Amos expects 2026 Japan sales to exceed 2025.
- Aflac U.S. sales +3.5%, earned premium +3.3%, persistency 79.7%, pretax margin 27.7%; momentum in group life, absence, disability and network dental.
- $1.1 billion returned to shareholders in Q3; 44 consecutive years of dividend increases.
- CFO Max Broden: about 500 billion yen of cancer reserves ceded to Aflac Re Bermuda, releasing about $1 billion of capital; ceded share of FSA reserves rose from 10% to 15% against a 30% internal limit.
- Broden on first sector savings (Tsumitasu): with higher yen rates Aflac can "significantly grow that business"; Tsumitasu is about 20% of Japan sales.
- CIO Brad Dyslin: $7 billion repositioned through switch trades this year, mostly JGBs; further trades will be harder to find.
- Japan sales were hit by the cyber incident (direct mail and outbound calls paused); activity resumed and October sales were as expected. U.S. group platform earned premium grew 17%; dental and vision sales up 67%.
- Aflac Q2 2026 CFO Video Update (Form 8-K Exhibit 99.3)
- Q2 2026 adjusted EPS rose 1.1% to $1.80 excluding foreign currency; variable investment income ran $72 million below expectations; a $26 million U.S. expense contingency release added $0.04.
- Adjusted ROE 12.7%, 16.6% excluding foreign currency remeasurement.
- Aflac Japan: net earned premiums -3.7% in yen, underlying earned premiums -1.4%; benefit ratio 64.0%; expense ratio 20.2%; pretax margin 34.3%; persistency 92.7%; 2026 benefit ratio guided to the high end of 60%-63% before the Q3 assumption review.
- Internal reinsurance target changed from up to 10% of U.S. GAAP assets to up to 30% of FSA reserves, to reduce risk and lift ROE.
- Aflac U.S.: net earned premiums +2.3%; 2026 premium growth now expected just below the 3%-6% range, while the 2025-2027 CAGR is still expected within it; benefit ratio 49.5% on higher group disability claims; pretax margin 20.9%.
- $4.8 billion repositioned through switch trades, expected to add over $50 million of run-rate net investment income.
- ESR 226% (240% with USP), combined RBC slightly above 600%; $983 million of buybacks and $309 million of dividends in Q2.
Questions about Aflac
What does Aflac do?
Aflac sells supplemental health and life insurance in Japan and the U.S., paying cash benefits for eligible claims to cover costs that primary coverage does not reimburse.
What is Aflac's revenue?
FY2025 total revenues were $17.2 billion; Q3 2026 total revenues were $3.3 billion.
How many employees does Aflac have?
12,716 full-time employees at end-2025, of whom 6,804 at Aflac Japan and 5,117 at Aflac U.S.
Who leads Aflac?
Daniel P. Amos is Chairman and CEO, Virgil R. Miller President of Aflac Incorporated and Max K. Brodén CFO; Shinsuke Morimoto and Fred Simard become presidents of Aflac Japan and Aflac U.S. from January 1.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)